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Many important drugs approved to treat common human diseases were discovered by
serendipity, without a ﬁrm understanding of their modes of action. As a result, the side
effects and interactions of these medications are often unpredictable, and there is limited
guidance for improving the design of next-generation drugs. Here, we review the innovative
use of simple model organisms, especially Caenorhabditis elegans, to gain fresh insights
into the complex biological effects of approved CNS medications.Whereas drug discovery
involves the identiﬁcation of new drug targets and lead compounds/biologics, and drug
development spans preclinical testing to FDA approval, drug elucidation refers to the
process of understanding the mechanisms of action of marketed drugs by studying their
novel effects in model organisms. Drug elucidation studies have revealed new pathways
affected by antipsychotic drugs, e.g., the insulin signaling pathway, a trace amine receptor
and a nicotinic acetylcholine receptor. Similarly, novel targets of antidepressant drugs and
lithium have been identiﬁed in C. elegans, including lipid-binding/transport proteins and
the SGK-1 signaling pathway, respectively. Elucidation of the mode of action of anesthetic
agents has shown that anesthesia can involve mitochondrial targets, leak currents, and
gap junctions. The general approach reviewed in this article has advanced our knowledge
about important drugs for CNS disorders and can guide future drug discovery efforts.
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INTRODUCTION
The process of developing new drugs is historically divided into
two phases that reﬂect the different goals and tasks of this complex
effort (Figure 1). Drug discovery is the initial phase characterized
by a search for appropriate targets or effects and identiﬁcation
of small molecules or biologics that selectively modulate those
targets (Hughes et al., 2011). A target is typically selected on the
basis of accumulated evidence linking it mechanistically to a dis-
ease, for example, mutation of the transmembrane conductance
regulator in cystic ﬁbrosis. However, for many CNS disorders,
the identity of the targets directly mediating the disorder (e.g.,
defective gene products or disease-causing variants) or even the
extended pathways that could be targeted for ameliorative effects
are not known with any certainty. The second phase of the process
is drug development, which is focused on promising drug can-
didates identiﬁed in discovery-stage research. The main goals of
this phase are to scale up chemistry and formulation, demonstrate
safety in animals, and ultimately, perform clinical trials to assess
tolerability and therapeutic beneﬁts in patients (Venkatesh and
Lipper, 2000).
This review article will focus on drug elucidation as a third
phase of drug discovery/development aimed at more thorough
characterization of the biological activities of FDA-approvedmed-
ications. We will begin with a broad discussion of the challenges
faced in developing new drugs for CNS disorders, and why it is,
therefore, important to fully characterize medications already on
themarket to treat these conditions. To illustrate this point, several
examples will be provided where the innovative use of Caenorhab-
ditis elegans has revealed novel ﬁndings or complemented other
work on the molecular actions of antipsychotics, antidepressants,
anesthetics, and other CNS drugs. Although the main focus is on
C. elegans as a model system, we will also occasionally highlight
the use of Drosophila and cell-based systems to gain insights into
these drug classes. Because the literature on these other systems
is extensive, we refer the reader to selected reviews that give a ﬂa-
vor for recent developments (Chiu and Chuang, 2010; Quesseveur
et al., 2013; Siebel et al., 2014; Urs et al., 2014). Finally, we will
outline how drug elucidation can guide future research directions
and possibly reveal new indications for existing drugs.
CHALLENGES IN THE DEVELOPMENT OF NEW AND
IMPROVED CNS DRUGS
Over the past several years, there have been unfortunate late-stage
failures of drugs in clinical trials of agents believed to be specif-
ically targeted to pathological mechanisms of various psychiatric
and neurological illnesses. This includes failure of a glutamate 2/3
receptor agonist (LY2140023) for schizophrenia (Stauffer et al.,
2013), preladenant, an adenosine 2A receptor antagonist aimed
www.frontiersin.org July 2014 | Volume 5 | Article 177 | 1
Dwyer et al. New light on CNS drugs
FIGURE 1 | Major activities of drug discovery, drug development, and
drug elucidation.The discovery process begins with the identiﬁcation of
appropriate targets or desired activities in biological assays (e.g.,
neuroprotection or cytotoxicity). Active compounds are then identiﬁed by
screening or de novo design, depending on knowledge about the target. The
activity of the lead compounds can be improved by rational drug design
(based on pharmacophore analysis or co-crystal structures with the receptor)
and medicinal chemistry. During the drug development stage, the chemistry
is scaled up, and pharmaceutical quality batches are produced for in vivo
testing. Drug candidates are evaluated for ADME properties and toxicity in
animals. Candidates clearing these hurdles are suitably formulated and
assessed in clinical trials. Success in these trials will determine whether a
drug receives FDA approval. Drug elucidation is achieved by ongoing
evaluation of marketed drugs in animals, including model organisms such as
C. elegans. Through a combination of pharmacology, genetics and behavioral
assessment, novel targets can be identiﬁed, and/or new insights into
therapeutic mechanisms and side effects can be obtained. This information
can then guide the next round of drug discovery and so on.
at Parkinson’s disease (Clinicaltrials. gov, 2013), and semagaces-
tat, a γ-secretase inhibitor for the treatment of Alzheimer’s disease
(Doody et al., 2013). There aremany possible reasons for these fail-
ures, including inadequate knowledge about suitable targets and
their relevant biology, redundancy in signaling pathways, pharma-
cokinetic issues that cast doubt on whether adequate therapeutic
levels of drug were achieved, off-target effects, the potential irre-
versibility of late-stage dysfunction in these disorders, and placebo
effects in control subjects. As a result of these and other setbacks,
most major pharmaceutical companies have dramatically reduced
or curtailed in-house research efforts to develop drugs for CNS
diseases. This decision is based largely on the realization that our
knowledge about the causes and pathogenesis of most of these
disorders is inadequate.
Regarding the role of genetic factors in disease causation,muta-
tion of a single gene or even a few genes rarely explains the risk
proﬁle or complex symptoms and patterns of functional decline
in patients with various CNS diseases. Instead, these conditions,
including schizophrenia and Parkinson’s disease, appear to result
from the deleterious effects of concurrent alterations in multiple
interacting genes, together with environmental effects. Thismeans
that, to be effective, either a drug must impact several proteins or
functional pathways, or a cocktail of several drugs must be used.
Evenwhen contributory genes have been identiﬁed [e.g., disrupted
in schizophrenia-1 (DISC1); Millar et al., 2001], CACNA1C in
several psychiatric disorders (Bhat et al., 2012), or α-synuclein in
Parkinson’s disease (Nussbaum and Polymeropoulos, 1997), their
precise roles in pathogenesis remain unclear. To address serious
gaps in our knowledge about the role of genetic factors, researchers
are now attempting to deconvolute CNS disorders into simpler
components, known as endophenotypes (Gottesman and Gould,
2003), which are the manifestations of genotypes associated with
speciﬁc aspects of a disease, e.g., dysconnectivity of regional neural
activity in schizophrenia (Karbasforoushan andWoodward,2012).
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Despite our limited understanding of disease causation, drugs
have successfully been developed to treat various psychiatric and
neurological conditions. For instance, chlorpromazine was devel-
oped to treat schizophrenia, lithium to treat bipolar disorder, and
riluzole for amyotrophic lateral sclerosis (ALS). Unfortunately,
many of these drugs produce only modest beneﬁts compared to
placebo, and none is considered a cure.
Currently available CNS drugs have, nevertheless, provided
useful clues about the diseases they target based on their putative
mechanisms of action. The pharmacological effects of antipsy-
chotics and Parkinson’s drugs implicate altered dopaminergic
function in schizophrenia (Carlsson,1974) andParkinson’s disease
(Cotzias et al., 1969). While dopamine is only part of the story in
these cases, the initial insights provide stepping stones for develop-
ing more comprehensive theories about the relevant mechanisms
of illness. Riluzole is the only FDA-approved drug for the treat-
ment of ALS (Cheah et al., 2010). Preclinical studies suggest that it
works, in part, by modulating glutamatergic neurotransmission,
and decreasing excitotoxicity, thereby reducing motorneuron loss
(Doble, 1996; Cheah et al., 2010). Similarly, the positive effects
of cholinesterase inhibitors on memory function in Alzheimer’s
patients support the idea of defective cholinergic function in this
disease (Greenwald and Davis, 1983). However, in each case, the
drugs may act downstream of the underlying pathological factors,
rather than at the source. Also, there is still much to learn about
the biological effects of the most efﬁcacious CNS drugs, and how
they can be improved. That is, the full effects of existing drugs are
still unknown, and deﬁning those effects potentially offers a rich
source of new insights into disease mechanisms, and guidance for
the development of next-generation therapeutics.
PROPERTIES OF DRUGS AND OFF-TARGET EFFECTS
Before discussing how drug elucidation has begun to reveal unex-
pected targets and novel biological effects, it is worth remarking
on the properties of the “perfect” CNS drug. Ideally, it would
be orally bioavailable, readily cross the blood brain barrier, show
high selectivity for its target, and produce no serious side effects.
To attain this gold standard, candidate molecules undergo a rig-
orous selection process biased toward drug-like properties (e.g.,
Lipinski’s rule of ﬁve; Lipinski et al., 1997; Brüstle et al., 2002).
Afﬁnity and selectivity are guiding forces in drug development,
yet they can also be impediments to truly rational drug design.
High afﬁnity is achieved by introducing chemical reactivity into
lead compounds. However, an increase in reactivity to improve
afﬁnitymay also increase the likelihoodof off-target binding, espe-
cially in the absence of 3-D structural information to maximize
complementarity at the binding site.
Selectivity is created by exploring different structural frame-
works and arranging reactive groups (pharmacophores) so that
binding is limited to the target receptor and possibly a few related
receptors (Dror et al., 2004; Kawasaki and Freire, 2011). However,
at therapeutic concentrations, many “selective” drugs will bind to
additional lower afﬁnity sites. Moreover, selectivity is established
by measuring binding to closely related receptors, for example,
additional G protein-coupled receptors (GPCR).However, screen-
ing across a wider range of target classes is also conducted, with
a particular focus on targets known to have safety liability, such
as the cardiac hERG channel. The production of active metabo-
lites, with different binding properties, further complicates drug
development.
It is interesting to consider whether the therapeutic effects of
a drug are due mainly to its interaction with the primary target,
which elicits very speciﬁc responses, or to interactions with awider
spectrum of proteins and broader biological activity. Antipsy-
chotic drugs (APD) havemultiplemolecularmechanisms (e.g., see
Cohen and Zubenko, 1985; Cohen and Lipinski, 1986). Moreover,
Roth et al. (2004) and others (Ma et al., 2006) have argued that
“dirty”drugs, with multiple effects, may actually be needed for the
treatment of schizophrenia and major depression. Antipsychotics
treat delusions and hallucinations in schizophrenia and bipolar
disorder, but they are also used off-label to treat a wide variety of
other neuropsychiatric conditions. Dopamine D2 receptor block-
ade is a shared feature of these widely used drugs, but it does
not appear to be their sole mechanism of action (Grunder et al.,
2009; Meltzer, 2013). Other targets likely to be relevant for the
therapeutic effects of antipsychotics include cholinergic receptors
(Ibrahim and Tamminga, 2011), glutamate and serotonin recep-
tors (Fribourg et al., 2011; Fell et al., 2012; de Bartolomeis et al.,
2013), andα-1noradrenergic receptors (Cohen andLipinski,1986;
Ma et al., 2006). These examples are not meant to be exhaustive,
but are listed here to illustrate the point that antipsychotics are
multi-target drugs (Roth et al., 2004) with additional molecular
mechanisms yet to be elucidated.
The presence of reactive substituents in drugs, non-selective
drug binding, drug accumulation in tissues or cells, and unantici-
pated actions of drugmetabolites all contribute to themost serious
consequence of off-target effects, namely, adverse events due to
drug treatment. Some of the adverse events are predictable based
on the pharmacological proﬁle of the drug. Oftentimes though,
the side effects are not explained by the known pharmacology,
and reveal novel, unsuspected drug targets. This new knowledge
can then be factored into the development of next-generation
drugs with less liability for causing harmful effects. Therefore,
it is important to have a comprehensive knowledge about the var-
ious targets of established medications to avoid side effects and
to determine the key activities desired in future drugs. In the
following sections, we describe how drug elucidation in model
organisms has provided valuable insights into APDs, antidepres-
sants, anesthetics and other CNS drugs, and the disorders that they
treat.
DRUG ELUCIDATION: NEW INSIGHTS INTO ANTIPSYCHOTIC
DRUGS
The classical view of APD action has focused on monoamine
and, especially, dopamine and serotonin receptor antagonism
(Figure 2). However, these are not the only sites where APDs
have direct or indirect effects. Drug elucidation studies in C.
elegans recently implicated the growth factor receptor DAF-2
and the ligand-gated ion channels (LGICs) ACR-7 and LGC-53
as APD targets (Karmacharya et al., 2009; Ringstad et al., 2009;
Weeks et al., 2010; Saur et al., 2013). DAF-2 is orthologous to
the mammalian insulin receptor, while ACR-7 is orthologous to
a mammalian nicotinic acetylcholine receptor (nAChR) α sub-
unit. LGC-53 is a tyramine-gated chloride channel, but whether
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FIGURE 2 | Elucidation of additional targets of antipsychotic drugs
(APDs). The classical view refers to drug targets identiﬁed during the
original development of ﬁrst- and second-generation APDs. The enriched
view depicts new targets identiﬁed in studies of these drugs in model
organisms, primarily C. elegans. The drugs appear to bind directly (as
indicated by solid arrows) to the ﬁrst layer of targets, and have important
secondary (red targets) and tertiary (blue targets) effects that are indirect
(dashed arrows). Although the ﬁrst-layer targets are depicted in parallel in
Figures 2–4, they may actually operate in series, or as components of
more extensive pathways. Gα-βγ denotes the G protein α and βγ subunits
associated with G protein-coupled receptors (GPCRs). DAF-2 is the
C. elegans insulin/IGF-1 receptor (InsR); PI3K is phosphatidylinositol
3-kinase; AKT and SGK-1 (serum- and glucocorticoid-inducible kinase-1) are
serine/threonine kinases.
LGC-53 has a mammalian ortholog remains unknown. APD
effects in C. elegans were also shown to require signaling by trace
amines, such as tyramine, a ﬁnding that was extended to mammals
(Karmacharya et al., 2011), though relevance to humans remains
untested.
Work from two independent groups showed that APDs acti-
vate the insulin signaling pathway (ISP) in C. elegans. First,
Karmacharya et al. (2009) demonstrated that mutations in the
insulin receptor gene daf-2 and in a downstream effector, the
phosphatidylinositol 3-kinase (PI3K) gene age-1, suppress lar-
val arrest induced by the atypical APD clozapine. Clozapine also
increased expression of an age-1::GFP reporter construct. Acti-
vation of the ISP is expected to cause cytoplasmic localization
of the fork head transcription factor FOXO/DAF-16. Consistent
with this expectation, clozapine produced cytoplasmic localiza-
tion of DAF-16::GFP in arrested L1 larvae, whereas DAF-16::GFP
was nuclear localized in L1 larvae arrested due to starvation or
high temperature. Subsequently, Weeks et al. (2010) showed that
all major classes of APDs increased signaling through the DAF-
2/AGE-1/AKT-1,2 pathway, as demonstrated by a decrease in
nuclear accumulation of DAF-16::GFP in starved C. elegans. The
same group had previously shown that atypical APDs increase Akt
phosphorylation in cultured mammalian neurons (Lu et al., 2004;
Lu and Dwyer, 2005), ﬁndings consistent with earlier suggestions
(Dwyer et al., 2003) and human genetic studies implicating dys-
function of the PI3K/AKT pathway in schizophrenia (Emamian
et al., 2004). The C. elegans results extended the mammalian data
by revealing speciﬁc mechanisms through which APDs induce Akt
phosphorylation and through which APDs may thereby compen-
sate for dysfunction of the PI3K/AKT pathway in schizophrenia.
The results may prove relevant not only for understanding the
fundamental pathogenetics of schizophrenia and the therapeutic
mechanisms of action of APDs but also for identifying mecha-
nisms underlying the toxic effects of APDs, such as metabolic
syndrome. For example, Gubert et al. (2013) showed that the
atypical antipsychotic ziprasidone altered lipid metabolism in C.
elegans in a DAF-16-dependent manner.
Clozapine is the most effective APD for treatment-refractory
schizophrenia, but the molecular basis of its unique therapeu-
tic efﬁcacy is not well understood (Meltzer, 2013). Cell-based
studies have identiﬁed additional targets of clozapine, including
T-type calcium channels (Choi and Rhim, 2010). Interestingly,
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drug elucidation studies in C. elegans revealed that clozapine dif-
fers from other APDs with respect to ISP activation. Clozapine’s
effects required two components of the pathway that other APDs
did not, the β-arrestin scaffolding protein ARR-1 and the serum-
and glucocorticoid-inducible kinase SGK-1 (Weeks et al., 2010,
2011). Thus, clozapine may activate PI3K/AGE-1 and SGK-1 via
β-arrestin/ARR-1 and may also act in parallel through PI3K/AGE-
1 and PDK-1 to activate AKT-1,2. Of possible relevance to these
observations, recent studies in C. elegans revealed that AKT-1
and SGK-1 affect lifespan, stress resistance, and DAF-16 activ-
ity in very different ways (Chen et al., 2013). For example, AKT-1
shortened lifespan, while SGK-1 promoted longevity in a DAF-16-
dependent manner. AKT-1 reduced stress resistance, while SGK-1
promoted resistance to oxidative stress and ultraviolet radiation.
AKT-1 promoted cytoplasmic localization of DAF-16, but SGK-
1 did not. Importantly, effects of sgk-1 mutations on DAF-16
target gene expression indicated that SGK-1 controlled DAF-16
targets through mechanisms that were distinct from those of AKT-
1 (Chen et al., 2013). These results raise the possibility that the
downstream consequences of ISP activation by clozapine may be
quite different from that of other APDs, possibly contributing
to the differential therapeutic effects of clozapine vis-à-vis other
APDs.
ISP activation is not the only clozapine-speciﬁc effect to
emerge from APD studies in C. elegans. Karmacharya et al.
(2011) showed that clozapine stimulated egg-laying, an effect not
seen with the typical antipsychotic haloperidol or the atypical
antipsychotic olanzapine. A candidate gene screen revealed that
clozapine-induced egg-laying required the gene tdc-1, responsible
for tyramine biosynthesis. The generalizability of these ﬁndings
to mammals was explored using trace amine-associated receptor
1 (TAAR1) knockout mice. Prepulse inhibition (PPI) of acoustic
startle is used to identify APDs that predict therapeutic beneﬁt
in patients, and clozapine increased PPI in wild-type mice. This
increase was abrogated in TAAR1 knockout mice, suggesting a role
for TAAR1 in clozapine-induced PPI enhancement (Karmacharya
et al., 2011).
While the discoveries of APD-induced ISP activation and
APD-induced trace amine signaling in C. elegans arose from
candidate gene screening, the power of invertebrate genetics to
elucidate fundamentally new drug targets lies ultimately in the
ability to conduct unbiased genetic screens for previously undoc-
umented targets. Recently, taking this unbiased approach, Saur
et al. (2013) reported a genome-wide RNA interference (RNAi)
screen in C. elegans for new APD targets. The screening strategy
took advantage of the developmental delay induced by APDs in
this organism (Donohoe et al., 2006; Karmacharya et al., 2009), a
phenotype thought to arise in part from APD-induced inhibition
of pharyngeal pumping (Donohoe et al., 2009; Saur et al., 2013).
Speciﬁcally, a genome-wide feeding RNAi screen was performed
for Suppressors of Clozapine-induced Larval Arrest (scla genes).
The primary screen tested 19,968wells, representing∼70%of cur-
rently annotated C. elegans genes, followed by subsequent testing
of primary screen positives in triplicate. The approach yielded 40
candidate suppressors, a number of which were then validated
using knockout mutants, including the α-like nAChR subunit
acr-7. Expression of a translational acr-7::GFP construct in the
acr-7 knockout partially rescued suppression of both clozapine-
induced developmental delay and clozapine-induced inhibition of
pharyngeal pumping. These clozapine-induced phenotypes were
phenocopied by nAChR agonists and blocked by nAChR antag-
onists. Taken as a whole, the results suggested that clozapine
activates theACR-7 receptor, a ﬁnding consistentwithmammalian
studies implicating nAChRs in the pathophysiology of schizophre-
nia (Harrison andWeinberger, 2005;Martin andFreedman,2007).
No other APDs have been shown to activate nAChRs, although
α7-nAChR agonists are currently being tested as treatments for
psychosis (Jones et al., 2012). Thus, α-like nAChR signaling con-
stitutes a mechanism through which clozapine, and possibly other
APDs, may produce their therapeutic or toxic effects in human
patients.
ACR-7 is homologous to a variety of human α-like nAChRs,
but the identity of the true ACR-7 ortholog is unknown. Mam-
mals have at least 17 different nAChR subunits, and these nAChRs
may assemble in a variety of functional combinations. Effects of
APDs on the spectrum of nAChR subunit combinations have not
been tested. Therefore, identifying the mammalian ortholog of
ACR-7 could resolve the important question of whether APDs can
activate one or more of these receptors. Detailed characterization
of other suppressors from the genome-wide RNAi screen of Saur
et al. (2013) is being conducted, as well.
A second LGIC, LGC-53, has emerged as a novel APD tar-
get from studies in C. elegans. The discovery originated from
studies of mutant genes in animals defective for Modulation
Of locomotion Defective (mod genes). First, Ranganathan et al.
(2000) showed that the gene mod-1 encodes a novel kind of sero-
tonin receptor, a serotonin-gated chloride channel. Ringstad et al.
(2009) then identiﬁed 26 presumptive Cys-loop family ion chan-
nels highly similar to MOD-1 and expressed them in oocytes
to test for receptor activity. Three genes were found to encode
biogenic amine-activated ion channels, and one of these, LGC-
53, was activated with highest efﬁcacy by dopamine and was
antagonized with IC50’s in the range of 20–60 μM for the APDs
haloperidol and risperidone. APDs can reach concentrations in
tissues where they are concentrated (e.g., brain and fat) that
are 20–30-fold higher than in serum (Tsuneizumi et al., 1992;
Kornhuber et al., 1999). These results raise the interesting pos-
sibility that the therapeutic and toxic effects of APDs may involve
inhibition of not only G protein-coupled dopamine receptors
but also dopamine-gated ion channels. As with ACR-7, the
next step in the LGC-53 project will be to identify a human
counterpart.
The studies reviewed here underscore several important points
regarding the mechanisms of APD action. First, the classical view
that APDs regulate dopaminergic and serotonergic signaling is
likely incomplete. Rather, APDs appear to interact with a variety
of signaling pathways, some of which are novel. Unbiased genetic
screens in animal models offer the possibility of identifying such
novel pathways. Second, dissecting these pathways may elucidate
targets that account for differences in the therapeutic efﬁcacy of
APDs. The role of SGK-1 in clozapine’s modulation of the ISP is
a potential case in point. Third, while genetic screens may open a
window onto new drug targets, follow-up studies of mammalian
orthologs of targets such as ACR-7 and LGC-53 are essential.
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ANTIDEPRESSANT DRUGS
Antidepressant drugs (ADs) are among the most prescribed class
of medications for adults between the ages of 20 and 59 and
are used to treat several emotional, behavioral, and neurologi-
cal problems (Gu et al., 2010). These include depression, anxiety,
obsessive–compulsive disorder, eating disorders, and both chronic
and neuropathic pain. Less commonly, doctors use these drugs
to treat other conditions including attention-deﬁcit hyperactivity
disorder, post-traumatic stress disorder, premenstrual dysphoria,
dysmenorrhea, migraines, sleep disorders, snoring and substance
abuse.
The most prescribed classes of AD are the selective serotonin
reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake
inhibitors (SNRIs), and the older tricyclic antidepressants (TCAs).
The classical view (Figure 3) is that these drugs improve mood
by blocking the reuptake of serotonin (5-HT) and/or nore-
pinephrine at the synaptic cleft and thus increase signaling by
these neurotransmitters.
ADs are effective in treating depression, but many patients
respond incompletely, andADs can have serious side effects.While
recent blinded studies indicate that antidepressants or psychother-
apies alone are only modestly better at symptom reduction than
active intervention controls (Khan et al., 2012), the beneﬁts of ADs
to those with more severe symptoms are better established. The
combination of psychotherapies and antidepressants may pro-
vide greater beneﬁt (Khan et al., 2012). Common side effects of
SSRIs and SNRIs include agitation during initiation of treatment,
restlessness, dry mouth, blurred vision, headache, sedation, and
elevated blood pressure. The list of side effects that are rare or for
which the incidence is unknown is extensive and includes several
that are very serious such as convulsions and suicide (Coupland
et al., 2011; PubMedHealth, 2013a). TCAs also have a very long list
of possible side effects, especially autonomic effects, and several are
again very serious (PubMed Health, 2013b). A clearer understand-
ing of the systems affected by these drugs should help researchers
identify more effective ADs with fewer side effects.
Antidepressants do more than block uptake of monoamine
neurotransmitters. Studieswithmammalian cells andmouse brain
slices in culture have shown that SSRIs and TCAs bind tightly to
several 5-HT receptor subtypes and act as either antagonists or
agonists depending on the receptor bound (Ni and Miledi, 1997;
Kroeze and Roth, 1998; Eisensamer et al., 2003). Mutations in C.
elegans that either eliminate 5-HT,or knock out the 5-HT reuptake
transporter, allowed several groups to show that the SSRI ﬂuoxe-
tine and the TCA imipramine can inﬂuence behavior independent
of 5-HT and 5-HT reuptake (Weinshenker et al., 1995; Choy and
Thomas, 1999; Sze et al., 2000; Ranganathan et al., 2001; Dempsey
et al., 2005; Kullyev et al., 2010).
Studies in C. elegans have also elucidated several new antide-
pressant targets (Figure 3). EGL-2, the C. elegans homolog of
ether-a-go-go, is a voltage-gated K+ channel required for egg-
laying, muscle activation, defecation, mechanosensation, and
chemosensation (Trent et al., 1983; Weinshenker et al., 1999; Wes
and Bargmann, 2001). Activating K+ channels can lower cellular
excitability, and inhibiting K+ channels can increase excitabil-
ity. Imipramine inhibits EGL-2 K+ currents and currents from
the mouse EGL-2 homolog mEAG (Weinshenker et al., 1999) and
may thereby increase cellular excitability, which may explain some
cardiac side effects. NRF-5 is a lipid-binding protein related to
mammalian cholesterol-ester-binding proteins. Choy et al. (2006)
FIGURE 3 | Novel targets of antidepressant drugs (ADs). According to
the classical view, ADs work by inhibiting neurotransmitter reuptake via
transporters of serotonin and norepinephrine. Drug elucidation has
revealed that these drugs also bind to EAG K+ channels, lipid-binding
proteins, additional transporters, and directly to particular serotonin
receptors.
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identiﬁed the nrf-5 and nrf-6 genes in a screen for mutations
that confer resistance to a ﬂuoxetine-induced nose contraction, an
effect that is independent of 5-HT reuptake. In the same genetic
pathway as nrf-5 are two genes that encode 12-pass transmem-
brane proteins, nrf-6 and ndg-4. Loss-of-function mutations in
each of these three genes reduce the ﬂuoxetine-induced nose con-
traction and result in pale eggs, presumably due to yolk and lipid
insufﬁciency. Together, NRF-5, NRF-6, and NDG-4 appear to be
involved in transporting ﬂuoxetine from the gut to its sites of
action.
Fluoxetine, imipramine, and 5-HT all stimulate egg-laying in
C. elegans. Deletion of SER-4, the C. elegans ortholog of the 5-HT1
receptor, strongly reduces egg-laying stimulated by imipramine
while leaving the egg-laying response to both 5-HT and ﬂuoxetine
intact (Dempsey et al., 2005). SER-7 is an ortholog of mammalian
5-HT7 GPCRs. Kullyev et al. (2010) found that ﬂuoxetine binds
directly to SER-7, and ser-7 loss-of-function mutants are resistant
to ﬂuoxetine-induced paralysis, a phenotype that is independent
of 5-HT reuptake. DAT-1 is a C. elegans dopamine reuptake trans-
porter. Very low imipramine concentrations (K i = 1 nm) block
dopamine reuptake activity of DAT-1 in both transiently trans-
fected HeLa cells (Jayanthi et al., 1998) and in C. elegans cells
in primary culture (Carvelli et al., 2004). Tricyclic ADs generally
have limited afﬁnity for human DATs (Buck and Amara, 1995).
A novel way in which Drosophila has aided drug elucidation is
by providing structural insights into nortriptyline binding to a
monoamine transporter. Penmatsa et al. (2013) solved the co-
crystal structure of the Drosophila dopamine transporter together
with nortriptyline. This information should assist structure-based
drug design.
Kullyev et al. (2010) also provided evidence for two additional
aspects of ﬂuoxetine action through genetic analyses in C. elegans.
First, they found that ﬂuoxetine regulates acetylcholine, GABA,
and glutamate neurotransmission in the locomotory circuit inde-
pendent of the sole 5-HT reuptake transporter, MOD-5. Second,
they found C. elegans neurons that contain, but do not synthe-
size, 5-HT. These cells obtain all of their 5-HT through uptake by
MOD-5. If neurons that obtain all of their 5-HT through uptake
also exist in humans, antidepressant treatment might eliminate
5-HT in speciﬁc subpopulations of neurons as well as increase
presynaptic 5-HT.
Cell-based studies showed that ADs modulate growth factor
expression inneuroblastoma cells (Henkel et al., 2008). These ﬁnd-
ings add to the list of evidence that implicates defective neuronal
plasticity in major depression and restored plasticity or outgrowth
as therapeutic. Moreover, this work addresses the important issue
of why ADs take several weeks to produce clinical beneﬁts. Of
course, binding to the targets mentioned above, including classi-
cal targets such as monoamine transporters, may elicit adaptive
changes in neurons that require several weeks to effect a beneﬁcial
outcome. Together, these studies identify additional antidepres-
sant targets and effects thatmay be important for either the clinical
action of these drugs or their side effects.
ANESTHETICS AND ALCOHOL
Our understanding of how anesthetics and alcohol work at the
molecular level has come a long way [compare Paton and Speden
(1965) and Kalant (1974) with Chau (2010) and Howard et al.
(2011)]. However, the picture is still incomplete, partly because
research has largely focused on how these agents affect individual
targets (e.g., GABAA receptors) in isolation. We now realize that
multiple proteins and other cell elements are affected, and that
the ﬁnal outcome involves complex interactions of the individ-
ual components. Although there is some overlap in the biological
actions of anesthetics and ethanol (Figure 4), these two classes of
agents will be discussed separately.
According to the classical view depicted in Figure 4, anesthetics
act by modulating various LGICs rather than membrane ﬂuidity
as previously believed. In general, they directly activate or poten-
tiate the response of inhibitory GABAA and glycine receptors,
and inhibit the activation of excitatory LGICs including nAChRs
and N-methyl-D-aspartate (NMDA) receptors (Krasowski and
Harrison, 1999; Antkowiak, 2001; Miller, 2002; Chau, 2010). Dif-
ferent types of anesthetic agents, e.g., intravenous (etomidate)
vs. gaseous (xenon) can act through distinct pathways (Nagele
et al., 2005; Forman and Miller, 2011). These and other exceptions
to a single mode of action point to the involvement of multiple
molecular mechanisms.
Drug elucidation studies in C. elegans have revealed genetic
mutations that cause either hypersensitivity or resistance to anes-
thetics (Simpson and Johnson, 1996; Morgan et al., 2007), and
the results are summarized in Figure 4. These mutations affect
neuronal function related to neurotransmitter release, postsynap-
tic responsiveness and/or mitochondrial energetics (e.g., gas-1).
Loss-of-functionmutations in the unc-79 and unc-80 genes, which
encodenovel proteins that are essential for the expression/function
of the Na+ leak-current channel (NALCN; NCA-1 and NCA-2
in C. elegans), cause hypersensitivity to halothane. In contrast,
loss-of-function mutations in unc-7 and unc-9, which encode gap
junction proteins, and unc-1 and unc-24, which encode stomatin
proteins, suppressed this hypersensitivity when introduced into
unc-79 or unc-80 (Sedensky and Meneely, 1987; Morgan et al.,
1990). Together, NCA-1/NCA-2, UNC-79, and UNC-80 augment
depolarization of neurons and vesicular release (Humphrey et al.,
2007;Yeh et al., 2008). Findings inC. elegans conﬁrm that anesthet-
ics also suppress vesicular release by directly binding to syntaxin
and/or SNARE complexes (van Swinderen et al., 1999). Finally,
anesthetics regulate neurotransmitter release by targeting G pro-
teins and various regulators of G proteins (van Swinderen et al.,
2001; Hawasli et al., 2004).
Based on the results of drug elucidation studies, we propose
the following scheme to explain the various actions of anes-
thetic agents. Anesthetics inhibit complex I activity via GAS-1
and associated proteins (Kayser et al., 1999; Falk et al., 2006).
This will decrease NAD+ leading to a concomitant reduction in
cADP ribose and nicotinic acid-adenine dinucleotide phosphate
(NAADP), which normally promote Ca++ release from internal
sites. The decrease in intracellular Ca++ reduces neurotransmitter
release, but not sufﬁciently to cause loss of consciousness. Anes-
thetic binding to syntaxin-SNARE complexes further compro-
mises neurotransmission. In addition, anesthetics bind to SLO-1
BK channels and potentiate anesthetic effects by hyperpolariz-
ing neurons (Hawasli et al., 2004). Loss-of-function mutations
in unc-79 and nca-1;nca-2 strains would enhance sensitivity to
www.frontiersin.org July 2014 | Volume 5 | Article 177 | 7
Dwyer et al. New light on CNS drugs
FIGURE 4 |Targets of anesthetics and ethanol identified in model
organisms. The classical view summarizes the main targets that have been
implicated in man and mice/rats, or in electrophysiological studies with
cells. The enriched view depicts novel targets identiﬁed in C. elegans, with
the exception of NDUSF4, which was found in mouse studies. NALCN+
associated proteins refers to the Na+ leak-current channel (NCA-1 and
NCA-2 in C. elegans) and proteins (UNC-79 and UNC-80) that regulate the
expression/function of NALCN. CLICs are chloride intracellular channels.
CRF stands for corticotropin-releasing factor, and NPY for neuropeptide Y.
While direct binding has not been established in all cases, we have
highlighted more direct effects with solid arrows and indirect effects with
dashed arrows.
certain anesthetics by decreasing depolarization-mediated Ca++
inﬂux. The absence of UNC-7 or UNC-9 reverses hypersensitiv-
ity in these strains by reducing functional gap junctions, which
blocks the spread of hyperpolarization, and/or prevents the dissi-
pation of positive signals (e.g., Ca++ inﬂux and NAD+) involved
in neurotransmitter release and excitation. Postsynaptic effects
of anesthetics on LGICs and voltage-gated ion channels add to
the deﬁcits in neurotransmission to produce anesthesia. Loss of
sensation and consciousness will depend on cumulative effects of
anesthetics on multiple targets. Finally, different anesthetics have
distinct modes of action related to the particular mix of primary
and secondary molecular targets they affect.
Ketamine is a dissociative anesthetic that, among other effects,
non-competitively inhibits NMDA receptors (Krystal et al., 1994;
Figure 4). Loss-of-function mutations in unc-68 reduce sensitivity
to ketamine and reveal the ryanodine receptor (RyR) as an addi-
tional target (Sakube et al., 1997). The RyR controls Ca++ release
from internal stores, which is consistent with the model presented
above. In addition, ketamine targets NDUSF4, an 18 kDa subunit
of mitochondrial complex I (Quintana et al., 2012). Ketamine also
inhibits the hyperpolarization-activated cation current channel
(HCN1), which results in extended hyperpolarization of neu-
rons (Chen et al., 2009). HCN1 knockout mice show a signiﬁcant
decrease in sensitivity to ketamine (Chen et al., 2009).
According to current thinking (classical view depicted in
Figure 4), ethanol mainly affects the function of voltage-
gated ion channels and LGICs (Dopico and Lovinger, 2009;
Howard et al., 2011). Drug elucidation studies reveal a
much more complex picture (McIntire, 2010). Ethanol over-
laps with anesthetics by directly affecting SLO-1 (Davies
et al., 2003), UNC-79 (Morgan and Sedensky, 1995), GAS-1
(Morgan and Sedensky, 1995), and proteins that regulate synap-
tic vesicle release, including UNC-18 (Graham et al., 2009) and
RAB-3 (Kapfhamer et al., 2008). Despite these cursory similar-
ities, there are differences, e.g., unc-79 loss of function causes
hypersensitivity to halothane (Sedensky and Meneely, 1987),
but resistance to ethanol (Morgan and Sedensky, 1995). Genetic
analysis in Drosophila,C. elegans and mice has revealed that muta-
tions in chloride intracellular channels (CLICs) also modulate
responsiveness to ethanol (Bhandari et al., 2012).
Work in C. elegans has also implicated neuropeptide Y (NPY)
and corticotropin releasing factor (CRF) signaling in the regula-
tion of ethanol responsiveness. More speciﬁcally, loss-of-function
mutations in the NPY receptor, npr-1, accelerate development
of acute tolerance to ethanol (Davies et al., 2004), and gain-of-
function mutations in the CRF receptor, seb-3, likewise enhance
recovery from ethanol exposure (Jee et al., 2013). Conversely, seb-
3(lf) mutants fail to develop acute tolerance to ethanol (Jee et al.,
2013). NPR-1 and SEB-3 do not appear to be direct targets; how-
ever, they play a signiﬁcant role in regulating behavioral responses
to ethanol. These drug elucidation studies in C. elegans have ther-
apeutic implications. For example, Jee et al. (2013) have suggested
that CRF1 receptor antagonists might be useful in the treatment
of alcoholism.
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OTHER CNS DRUGS IN CLINICAL USE: LITHIUM AND
RILUZOLE
Lithium is a front-line treatment for bipolar disorder (Malhi et al.,
2012). Although it is perhaps the simplest CNS drug of all in terms
of structure, being an element, not amolecule, lithium’s actions are
diverse, and its therapeuticmechanisms arenot fully characterized.
Classically, lithium is considered to work by affecting neurotrans-
mitter release, monoamine metabolism and neuronal excitability
by directly targeting G proteins, myo-inositol monophosphatase
(IMP) and glycogen synthase kinase-3α (GSK-3α; Phiel and Klein,
2001; Can et al., 2014). Research on Drosophila has identiﬁed the
Wnt signaling pathway as a target of lithium (Berger et al., 2005).
Recent ﬁndings in C. elegans have also advanced our understand-
ing of how this drug may affect the CNS. Weeks et al. (2011)
discovered that 5 mM lithium activates SGK-1 via a signaling
pathway that includes G proteins and β-arrestin. This leads to
phosphorylation of the FOXO protein, DAF-16, and its exclusion
from the nucleus. Although 5 mM lithium is somewhat higher
than the serum therapeutic range in humans (∼1 mM), in C.
elegans a cuticle barrier limits uptake of drug, so in vivo concentra-
tions are substantially less than the concentration on the culture
plate (McColl et al., 2008). Activation of the SGK-1 pathway is
neuroprotective (Schoenebeck et al., 2005), which may account
for some of the beneﬁcial clinical effects of lithium. Moreover,
lithium’s effects on SGK-1, a regulator of extracellular ﬂuid vol-
ume and sodium homeostasis (Chen et al., 1999),may explain why
this drug can induce diabetes insipidus (Bendz and Aurell, 1999)
and hypertension (Vestergaard et al., 1980).
Intriguingly, lithium extends lifespan in C. elegans via mech-
anisms independent of its actions on insulin signaling/DAF-16
(McColl et al., 2008). In these experiments, animals are chronically
exposed to 10 mM lithium on plates, with in vivo concentra-
tions estimated to reach 1.2 mM. Genomics studies suggest that
changes in histone methylation and chromatin structure mediate
the increase in longevity. Whether similar changes in brain con-
tribute to the therapeutic actions of lithium in bipolar disorder is
a matter of speculation, and a topic for further study.
Riluzole is the only drug currently approved for the treat-
ment of ALS (Gordon et al., 2013). It is thought to spare motor
neuron function by decreasing excitotoxicity via direct effects
on glutamate release, glutamatergic signaling, and Na+ chan-
nel inactivation (Doble, 1996). Recent drug elucidation studies
of riluzole in C. elegans reveal additional targets. Riluzole causes
rapid ﬂaccid paralysis of wild-type, young adult C. elegans (Dwyer
and Aamodt, unpublished observations). Strains harboring dou-
ble (avr-14;avr-15) or triple (avr-14;avr-15;glc-1) loss-of-function
mutations in glutamate-activated chloride channels are signiﬁ-
cantly resistant to the effects of riluzole. These C. elegans LGICs
are most homologous to human glycine receptors (GLRA1-3) that
have been implicated in excessive startle syndromes (hyperek-
plexia) inman (Davies et al., 2010). The double- and triple-mutant
strains are also resistant to ivermectin, a nematocidal drug that is
an allosteric activator of glutamate-activated chloride channels
leading to extended hyperpolarization and paralysis (Dent et al.,
2000). Taken together, these studies in C. elegans suggest exciting
new directions for research in several areas: (1) glycine receptors
may be additional targets of riluzole (Mohammadi et al., 2001) and
play a role in the pathogenesis of ALS, (2) riluzolemay be beneﬁcial
in the treatment of hyperekplexia, and (3) riluzole might serve as
a lead compound for the development of new anthelmintic agents
that overcome emerging drug resistance to ivermectin and related
drugs.
DRUG ELUCIDATION DRIVES DISCOVERY RESEARCH
In this review, we have provided numerous examples where
drug elucidation in model organisms led to the identiﬁcation
of novel, unexpected targets of CNS drugs. Beyond these dis-
coveries, drug elucidation studies potentially impact three major
areas of research: (1) the development of next-generation drugs,
(2) minimization of drug side effects by the avoidance of certain
targets in future drugs, and (3) the fundamental understanding
of disease mechanisms. Although we picture drug elucidation as
a stage that follows drug development, i.e., characterization of
drugs already in clinical use, it may also guide new drug discovery
as part of an iterative cycle (Figure 5). Novel targets identiﬁed
through drug elucidation become new focal points for the next
round of drug discovery. Trace amine receptors in schizophrenia
and glycine receptors in ALS are two examples of this prospective
approach.
Drug elucidation studies have already provided insights into
the side effects of CNS drugs. For example, clozapine and lithium
affect SGK-1 signaling, which may explain why these drugs are
associated with induction of diabetes insipidus and elevated blood
pressure (Weeks et al., 2011). Similarly, ketamine’s effects on the
mitochondrial protein NDUSF4 or the RyR may contribute to its
reported neurotoxicity (Olney et al., 1989; Scallet et al., 2004). The
challenge will be to tease apart the mechanisms causing side effects
from those producing therapeutic beneﬁts. Model organisms can
be useful in this effort as already demonstrated in C. elegans
(Donohoe et al., 2006; Karmacharya et al., 2009).
Identiﬁcation of new targets of approved medications via drug
elucidation also expands our knowledge about the pathogenesis
FIGURE 5 | Drug elucidation can drive drug discovery. Drug research
activities have been depicted in a connected circle to highlight how iterative
cycles may operate. Accordingly, drug elucidation is both downstream of
drug development (i.e., it focuses on FDA-approved medications) and
upstream of drug discovery – identiﬁcation of novel targets suggests new
directions for discovery research. By repeating this cycle with medications
already shown to be effective, new drugs can be discovered with fewer
side effects and a more rational mode of action.
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of the corresponding diseases. For example, the independent dis-
covery by two groups that APDs activate ISP-Akt signaling in C.
elegans (Karmacharya et al., 2009; Weeks et al., 2010) is consis-
tent with other evidence suggesting a role for this pathway in
schizophrenia. Akt was previously implicated in schizophrenia
because single nucleotide polymorphisms in the AKT1 gene were
associated with increased risk for this disease, and levels of Akt-
1 were reduced in the brains and peripheral blood lymphocytes
of schizophrenic patients (Emamian et al., 2004). The prospect of
Akt as an attractive therapeutic target in schizophrenia has been
discussed in detail elsewhere (Kalkman, 2006; Dwyer and Dick-
son, 2007). Moreover, the effect of APDs on DAF-16 is especially
interesting in view of the fact that this transcription factor reg-
ulates the expression of tyrosine hydroxylase (Ferri et al., 2007)
and tryptophan hydroxylase (Estevez et al., 2006), and thus the
production of dopamine and serotonin, respectively. Importantly,
this observation provides a link between the genetics and neu-
rochemistry of schizophrenia and its associated impairment of
neuronal function [Akt mediates neuron growth (Dudek et al.,
1997; Philpott et al., 1997), soma size (Kumar et al., 2005) and
regulates the caliber of neuronal processes (Markus et al., 2002)].
The discovery of trace amine receptors (Karmacharya et al., 2011)
and the α7-nicotinic receptor (Saur et al., 2013) as targets of APDs
in C. elegans spotlight these pathways as candidates for involve-
ment in the pathogenesis of schizophrenia. A role of nicotinic
cholinergic systems in schizophrenia has long been suspected
based on the high rates of smoking in schizophrenic patients
(Freedman et al., 1994).
Similarly, drug elucidation studies of medications used clin-
ically (ADs) or experimentally (ketamine) to treat depressed
patients reveal additional signaling mechanisms that should be
factored into models about causes of major depression. For exam-
ple, it is noteworthy that human RyR genes, RYR1 and RYR3, are
encoded at sites, 19q13 and 15q14–15, respectively, which have
been implicated as risk loci for bipolar disorder in genome-wide
association studies (Reif et al., 2004; Francks et al., 2010; Green
et al., 2013). Alternatively, these targets may be involved in side
effects of ADs such as ventricular tachycardia (Thanacoody and
Thomas, 2005; Zima et al., 2008). As discussed here, drug elu-
cidation studies can generate new ideas about disease causation
and the adverse effects of psychotropic drugs, and ultimately
provide a deeper understanding of CNS disorders. Research on
drug effects in model organisms is an essential ingredient of these
efforts because genetic manipulations in these systems, especially
C. elegans, are typically more powerful tools than in mammalian
models.
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